company background image
INZY

Inozyme PharmaNasdaqGS:INZY Stock Report

Last Price

US$6.67

Market Cap

US$157.8m

7D

-2.6%

1Y

-74.7%

Updated

19 Jan, 2022

Data

Company Financials +
INZY fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

INZY Stock Overview

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases.

Price History & Performance

Summary of all time highs, changes and price drops for Inozyme Pharma
Historical stock prices
Current Share PriceUS$6.67
52 Week HighUS$28.42
52 Week LowUS$5.33
Beta0
1 Month Change-11.54%
3 Month Change-30.08%
1 Year Change-74.66%
3 Year Changen/a
5 Year Changen/a
Change since IPO-61.97%

Recent News & Updates

Dec 22
Here's Why We're Not Too Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Situation

Here's Why We're Not Too Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Sep 08
Companies Like Inozyme Pharma (NASDAQ:INZY) Are In A Position To Invest In Growth

Companies Like Inozyme Pharma (NASDAQ:INZY) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

INZYUS BiotechsUS Market
7D-2.6%-2.5%-0.3%
1Y-74.7%-14.3%13.7%

Return vs Industry: INZY underperformed the US Biotechs industry which returned -14.3% over the past year.

Return vs Market: INZY underperformed the US Market which returned 13.7% over the past year.

Price Volatility

Is INZY's price volatile compared to industry and market?
INZY volatility
INZY Average Weekly Movement10.8%
Biotechs Industry Average Movement10.0%
Market Average Movement6.6%
10% most volatile stocks in US Market15.9%
10% least volatile stocks in US Market2.4%

Stable Share Price: INZY is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: INZY's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201538Axel Boltehttps://www.inozyme.com

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company’s lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products.

Inozyme Pharma Fundamentals Summary


Earnings & Revenue

Key profitability statistics from the latest earnings report
INZY income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
ExpensesUS$48.99m
Earnings-US$48.99m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-2.07
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did INZY perform over the long term?

See historical performance and comparison

Valuation

Is Inozyme Pharma undervalued compared to its fair value and its price relative to the market?

1.25x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate INZY's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate INZY's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: INZY is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: INZY is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate INZY's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: INZY is good value based on its PB Ratio (1.3x) compared to the US Biotechs industry average (2.2x).


Future Growth

How is Inozyme Pharma forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

-7.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: INZY is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: INZY is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: INZY is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: INZY is forecast to have no revenue next year.

High Growth Revenue: INZY is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if INZY's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Inozyme Pharma performed over the past 5 years?

5.5%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: INZY is currently unprofitable.

Growing Profit Margin: INZY is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if INZY's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare INZY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: INZY is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).


Return on Equity

High ROE: INZY has a negative Return on Equity (-38.89%), as it is currently unprofitable.


Financial Health

How is Inozyme Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: INZY's short term assets ($130.6M) exceed its short term liabilities ($8.9M).

Long Term Liabilities: INZY's short term assets ($130.6M) exceed its long term liabilities ($2.8M).


Debt to Equity History and Analysis

Debt Level: INZY is debt free.

Reducing Debt: INZY has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: INZY has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: INZY has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 48.8% each year.


Dividend

What is Inozyme Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate INZY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate INZY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if INZY's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if INZY's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of INZY's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.9yrs

Average management tenure


CEO

Axel Bolte (49 yo)

6.33yrs

Tenure

US$5,355,634

Compensation

Mr. Axel Bolte, M.Sc. & M.B.A. serves as the President, Chief Executive Officer and Director of Inozyme Pharma, Inc. since September 2015. He is a Co-Founder of Inozyme Pharma, Inc. Since March 2017, Mr. B...


CEO Compensation Analysis

Compensation vs Market: Axel's total compensation ($USD5.36M) is above average for companies of similar size in the US market ($USD1.10M).

Compensation vs Earnings: Axel's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: INZY's management team is considered experienced (2.9 years average tenure).


Board Members

Experienced Board: INZY's board of directors are considered experienced (3.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Inozyme Pharma, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Inozyme Pharma, Inc.
  • Ticker: INZY
  • Exchange: NasdaqGS
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$157.844m
  • Shares outstanding: 23.66m
  • Website: https://www.inozyme.com

Number of Employees


Location

  • Inozyme Pharma, Inc.
  • 321 Summer Street
  • Suite 400
  • Boston
  • Massachusetts
  • 2210
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/19 00:12
End of Day Share Price2022/01/18 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.